368 related articles for article (PubMed ID: 17103262)
1. Type and duration of exogenous hormone use affects breast cancer histology.
Kumar AS; Cureton E; Shim V; Sakata T; Moore DH; Benz CC; Esserman LJ; Hwang ES
Ann Surg Oncol; 2007 Feb; 14(2):695-703. PubMed ID: 17103262
[TBL] [Abstract][Full Text] [Related]
2. Menopausal hormone therapy and breast cancer phenotype: does dose matter?
Garwood ER; Kumar AS; Shim V
Ann Surg Oncol; 2008 Sep; 15(9):2526-32. PubMed ID: 18618187
[TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users.
Kumar AS; Benz CC; Shim V; Minami CA; Moore DH; Esserman LJ
Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1028-33. PubMed ID: 18463402
[TBL] [Abstract][Full Text] [Related]
4. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma.
Chen WY; Hankinson SE; Schnitt SJ; Rosner BA; Holmes MD; Colditz GA
Cancer; 2004 Oct; 101(7):1490-500. PubMed ID: 15378477
[TBL] [Abstract][Full Text] [Related]
5. Association of regimens of hormone replacement therapy to prognostic factors among women diagnosed with breast cancer aged 50-64 years.
Daling JR; Malone KE; Doody DR; Voigt LF; Bernstein L; Marchbanks PA; Coates RJ; Norman SA; Weiss LK; Ursin G; Burkman RT; Deapen D; Folger SG; McDonald JA; Simon MS; Strom BL; Spirtas R
Cancer Epidemiol Biomarkers Prev; 2003 Nov; 12(11 Pt 1):1175-81. PubMed ID: 14652277
[TBL] [Abstract][Full Text] [Related]
6. Estrogen and progesterone receptor status in breast cancer: effect of oral contraceptive pills and hormone replacement therapy.
Tewari M; Pradhan S; Singh U; Shukla HS
Breast; 2007 Oct; 16(5):540-5. PubMed ID: 17587581
[TBL] [Abstract][Full Text] [Related]
7. Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: a cohort study.
Dew JE; Wren BG; Eden JA
Climacteric; 2002 Jun; 5(2):151-5. PubMed ID: 12051110
[TBL] [Abstract][Full Text] [Related]
8. Hormone replacement therapy and mammographic screening outcomes in Western Australia.
Crouchley K; Wylie E; Khong E
J Med Screen; 2006; 13(2):93-7. PubMed ID: 16792833
[TBL] [Abstract][Full Text] [Related]
9. Use of HRT and the subsequent risk of cancer.
Beral V; Banks E; Reeves G; Appleby P
J Epidemiol Biostat; 1999; 4(3):191-210; discussion 210-5. PubMed ID: 10695959
[TBL] [Abstract][Full Text] [Related]
10. Short-term biologic response to withdrawal of hormone replacement therapy in patients with invasive breast carcinoma.
Prasad R; Boland GP; Cramer A; Anderson E; Knox WF; Bundred NJ
Cancer; 2003 Dec; 98(12):2539-46. PubMed ID: 14669271
[TBL] [Abstract][Full Text] [Related]
11. Impact of hormone replacement therapy on the histologic subtype of breast cancer.
Zanetti-Dällenbach RA; Krause EM; Lapaire O; Gueth U; Holzgreve W; Wight E
Arch Gynecol Obstet; 2008 Nov; 278(5):443-9. PubMed ID: 18335229
[TBL] [Abstract][Full Text] [Related]
12. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden.
Olsson HL; Ingvar C; Bladström A
Cancer; 2003 Mar; 97(6):1387-92. PubMed ID: 12627501
[TBL] [Abstract][Full Text] [Related]
13. Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy.
Schuetz F; Diel IJ; Pueschel M; von Holst T; Solomayer EF; Lange S; Sinn P; Bastert G; Sohn C
Am J Obstet Gynecol; 2007 Apr; 196(4):342.e1-9. PubMed ID: 17403414
[TBL] [Abstract][Full Text] [Related]
14. Unopposed estrogen therapy and the risk of invasive breast cancer.
Chen WY; Manson JE; Hankinson SE; Rosner B; Holmes MD; Willett WC; Colditz GA
Arch Intern Med; 2006 May; 166(9):1027-32. PubMed ID: 16682578
[TBL] [Abstract][Full Text] [Related]
15. Effect modification by catalase genotype suggests a role for oxidative stress in the association of hormone replacement therapy with postmenopausal breast cancer risk.
Quick SK; Shields PG; Nie J; Platek ME; McCann SE; Hutson AD; Trevisan M; Vito D; Modali R; Lehman TA; Seddon M; Edge SB; Marian C; Muti P; Freudenheim JL
Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1082-7. PubMed ID: 18483329
[TBL] [Abstract][Full Text] [Related]
16. Reproductive factors, hormone use, estrogen receptor expression and risk of non small-cell lung cancer in women.
Schwartz AG; Wenzlaff AS; Prysak GM; Murphy V; Cote ML; Brooks SC; Skafar DF; Lonardo F
J Clin Oncol; 2007 Dec; 25(36):5785-92. PubMed ID: 18089876
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for hormone receptor-defined breast cancer in postmenopausal women.
Rosenberg LU; Einarsdóttir K; Friman EI; Wedrén S; Dickman PW; Hall P; Magnusson C
Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2482-8. PubMed ID: 17164374
[TBL] [Abstract][Full Text] [Related]
18. A case-control study of hormone replacement therapy after primary surgical breast cancer treatment.
Ursic-Vrscaj M; Bebar S
Eur J Surg Oncol; 1999 Apr; 25(2):146-51. PubMed ID: 10218456
[TBL] [Abstract][Full Text] [Related]
19. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
Bartlett JM; Ellis IO; Dowsett M; Mallon EA; Cameron DA; Johnston S; Hall E; A'Hern R; Peckitt C; Bliss JM; Johnson L; Barrett-Lee P; Ellis P
J Clin Oncol; 2007 Oct; 25(28):4423-30. PubMed ID: 17906205
[TBL] [Abstract][Full Text] [Related]
20. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
